Human AD patients carrying the TREM2 risk variants have more dystrophic microglia, weaker interaction of microglia with amyloid plaques, increased dystrophic neurites, and larger areas of insoluble phosphorylated tau than age- and disease stage-matched AD patients without an AD risk variant [55, 56]. This evidence concerns the gene MAPT and Alzheimer disease.